Pre-Surgery Erlotinib for Head and Neck Cancer
Trial Summary
What is the purpose of this trial?
This randomized phase Ib trial studies standard-dose or high-dose erlotinib hydrochloride before surgery in treating patients with head and neck cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Research Team
Xiuning Le, M.D., Ph.D.
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for adults with head and neck cancer, including salivary gland tumors and aggressive skin squamous cell carcinoma. Candidates must be able to undergo surgery, have a performance score of 0-2, adequate organ function, and agree to use contraception. It's not for those needing immediate surgery or with serious health issues like heart disease.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either standard-dose or high-dose erlotinib hydrochloride orally once daily for 2-3 weeks, up to 8 weeks if surgery is delayed
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Erlotinib Hydrochloride
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator